Pharmaceutical composition

A pharmaceutical composition comprising a compound represented by the formula (I):

• 201
• wherein R is an aliphatic hydrocarbon group optionally having substituents, an aromatic hydrocarbon group optionally having substituents, a heterocyclic group optionally having substituents, a group represented by the formula:
• —OR1 (wherein R1 is a hydrogen atom or an aliphatic hydrocarbon group optionally having substituents) or a group represented by the formula:
• 202
• wherein R1b is a hydrogen atom or an aliphatic hydrocarbon group optionally having substituents, R1c is the same as or different from R1b and is a hydrogen atom or an aliphatic hydrocarbon group optionally having substituents, R0 is a hydrogen atom or an aliphatic hydrocarbon group, or R and R0 in combination represent a bond, ring A1 is a cycloalkene optionally substituted by 1 to 4 substituents selected from (1) an aliphatic hydrocarbon group optionally having substituents, (2) an aromatic hydrocarbon group optionally having substituents, (3) a group represented by the formula:
• —OR1 (wherein R1 is as defined above) and (4) a halogen atom, Ar is an aromatic hydrocarbon group optionally having substituents, a group represented by the formula:
• 203
• represents a group represented by the formula:
• 204
• and n is an integer of 1 to 4, a salt thereof or a prodrug thereof, and a nonionic surfactant.

A method for improving solubility, stability or coloring property of a compound represented by the formula (I):

• 205
• wherein R is an aliphatic hydrocarbon group optionally having substituents, an aromatic hydrocarbon group optionally having substituents, a heterocyclic group optionally having substituents, a group represented by the formula:
• —OR1 (wherein R1 is a hydrogen atom or an aliphatic hydrocarbon group optionally having substituents) or a group represented by the formula:
• 206
• wherein R1b is a hydrogen atom or an aliphatic hydrocarbon group optionally having substituents, R1c is the same as or different from R1b and is a hydrogen atom or an aliphatic hydrocarbon group optionally having substituents, R0 is a hydrogen atom or an aliphatic hydrocarbon group, or R and R0 in combination represent a bond, ring A1 is a cycloalkene optionally substituted by 1 to 4 substituents selected from (1) an aliphatic hydrocarbon group optionally having substituents, (2) an aromatic hydrocarbon group optionally having substituents, (3) a group represented by the formula:
• —OR1 (wherein R1 is as defined above) and (4) a halogen atom, Ar is an aromatic hydrocarbon group optionally having substituents, a group represented by the formula:
• 207
• represents a group represented by the formula:
• 208
• and n is an integer of 1 to 4, a salt thereof or a prodrug thereof, which comprises mixing said compound, a salt thereof or a prodrug thereof, with a nonionic surfactant.

A pharmaceutical composition comprising a compound represented by the formula (I):

• 209
• wherein R is an aliphatic hydrocarbon group optionally having substituents, an aromatic hydrocarbon group optionally having substituents, a heterocyclic group optionally having substituents, a group represented by the formula:
• —OR1 (wherein R1 is a hydrogen atom or an aliphatic hydrocarbon group optionally having substituents) or a group represented by the formula:
• 210
• wherein R1b is a hydrogen atom or an aliphatic hydrocarbon group optionally having substituents, R1c is the same as or different from R1b and is a hydrogen atom or an aliphatic hydrocarbon group optionally having substituents, R0 is a hydrogen atom or an aliphatic hydrocarbon group, or R and R0 in combination represent a bond, ring A1 is a cycloalkene optionally substituted by 1 to 4 substituents selected from (1) an aliphatic hydrocarbon group optionally having substituents, (2) an aromatic hydrocarbon group optionally having substituents, (3) a group represented by the formula:
• —OR1 (wherein R1 is as defined above) and (4) a halogen atom, Ar is an aromatic hydrocarbon group optionally having substituents, a group represented by the formula:
• 211
• represents a group represented by the formula:
• 212
• and n is an integer of 1 to 4, a salt thereof or a prodrug thereof, and a cyclodextrin derivative readily soluble in water.

A method for improving solubility in water, stability or coloring property of a compound represented by the formula (I):

• 214
• wherein R is an aliphatic hydrocarbon group optionally having substituents, an aromatic hydrocarbon group optionally having substituents, a heterocyclic group optionally having substituents, a group represented by the formula:
• —OR1 (wherein R1 is a hydrogen atom or an aliphatic hydrocarbon group optionally having substituents) or a group represented by the formula:
• 215
• wherein R1b is a hydrogen atom or an aliphatic hydrocarbon group optionally having substituents, R1c is the same as or different from R1b and is a hydrogen atom or an aliphatic hydrocarbon group optionally having substituents, R0 is a hydrogen atom or an aliphatic hydrocarbon group, or R and R0 in combination represent a bond, ring A1 is a cycloalkene optionally substituted by 1 to 4 substituents selected from (1) an aliphatic hydrocarbon group optionally having substituents, (2) an aromatic hydrocarbon group optionally having substituents, (3) a group represented by the formula:
• —OR1 (wherein R1 is as defined above) and (4) a halogen atom, Ar is an aromatic hydrocarbon group optionally having substituents, a group represented by the formula:
• 216
• represents a group represented by the formula:
• 217
• and n is an integer of 1 to 4, a salt thereof or a prodrug thereof, which comprises mixing said compound, a salt thereof or a prodrug thereof with a cyclodextrin derivative readily soluble in water.